Core Viewpoint - Tango Therapeutics, Inc. is actively participating in multiple investment bank conferences to showcase its advancements in precision cancer medicines and engage with investors [1]. Group 1: Upcoming Conferences - Tango Therapeutics management will participate in the B Riley Precision Oncology & Radiopharma Conference in New York, NY in late February [1]. - The Leerink Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference will take place in Miami, FL in March [1]. - The company will be available for 1x1 meetings on Thursday, March 13 [2]. Group 2: Webcast Information - Live webcasts for each event will be available under the "Events & Presentations" tab on the company's website on the day of the event [2]. - A replay of the webcasts will be archived on the company's website for 90 days following the presentations [2]. Group 3: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [4]. - The company utilizes the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related pathways [4].

Core Insights - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision cancer medicines [1][3] - The company will participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025 [1] - The event will be accessible via a live webcast and will be archived for 90 days on the company's website [2] Company Overview - Tango Therapeutics is dedicated to discovering novel drug targets and precision medicine for cancer treatment [3] - The company employs the genetic principle of synthetic lethality to develop therapies targeting critical cancer-related targets [3] - More information about the company can be found on their website [3]

Earnings season has begun, and I managed to find a few nuances in Tango Therapeutics (NASDAQ: TNGX ) that motivated me to take a long position via long options on thisHi, I'm Martin, I focus on maintaining a delta neutral portfolio. I want to be long/short at the same time and benefit from market volatility. I specialize in using options through which I enter and exit trades. I look for market opportunities primarily in small companies, and my search takes me into the waters of mid-sized companies as well.A ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $0.24, delivering a surprise of 29.41%.Over the last four quarters, the company has ...

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the ...

Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 29.41%. A quarter ago, it was expected that this company would post a loss of $0.31 per share when it actually produced a loss of $0.35, delivering a surprise of -12.90%. Over the last four quarters, the company ...

Core Viewpoint - The market anticipates Tango Therapeutics, Inc. (TNGX) will report a year-over-year decline in earnings due to lower revenues, with actual results being crucial for stock price movement [1]. Revenue Expectations - Revenues for the upcoming quarter are projected to be $7.39 million, reflecting a significant decrease of 49.4% compared to the same quarter last year [2]. Earnings Estimates and Revisions - The consensus EPS estimate for Tango Therapeutics has been revised down by 2.76% over the last 30 days, indicating a reassessment by analysts [9]. - The Most Accurate Estimate for Tango Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -7.39%, suggesting a bearish outlook on the company's earnings prospects [22]. Earnings Performance History - Over the last four quarters, Tango Therapeutics has beaten consensus EPS estimates twice, but the company is not currently viewed as a strong candidate for an earnings beat [12][24]. Industry Context - In comparison, Blueprint Medicines (BPMC), another player in the biomedical and genetics industry, is expected to report a loss of $1.28 per share, which represents a year-over-year change of +41.6%, with revenues anticipated to be $104.55 million, up 81.6% from the previous year [31].

Tango Therapeutics, Inc. (TNGX) shares soared 6.7% in the last trading session to close at $9.89. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.2% loss over the past four weeks. This company is expected to post quarterly loss of $0.34 per share in its upcoming report, which represents a year-over-year change of -47.8%. Revenues are expected to be $7.39 million, down 49.4% from the year-ago quarter. For Tango Therapeutics, the ...

Last month, the company announced robust financial results for the first quarter of 2024. It also provided an update on its promising set of pipeline candidates, which are being developed as the next generation of precision medicines for the treatment of cancer. Several clinical milestones are expected later in 2024. This may have been driving the share price rally. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong ...

https://news.cision.com/medivir/r/medivir-s-licensee--tango-therapeutics--has-discontinued-development-of-its- tng348-clinical-program,c3987012 STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being ...